Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Small Cell Lung Carcinoma 2

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × lorvotuzumab mertansine × Thoracic × Clear all
NCT01237678 2018-01-18

A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

ImmunoGen, Inc.

Phase 1/2 Terminated
181 enrolled 17 charts
Thoracic

Small Cell Lung Carcinoma

NCT00065429 2012-07-18

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

ImmunoGen, Inc.

Phase 1/2 Completed
64 enrolled 13 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡